Revolution Medicines Inc. has been on a roll during the past year after entering into a partnership with Sanofi to develop its SHP2 inhibitor, buying Warp Drive Bio Inc. to bolster its cancer drug discovery capabilities and raising a $100m series C venture capital round to accelerate its development of small molecules that target various mutations in the RAS pathway downstream from SHP2.
The series C financing disclosed on 9 July was one of four $100m-plus VC funding rounds announced by biopharmaceutical companies...